Wang Peipei, Chen Song, Fang He, Wu Xiaojuan, Chen Dabiao, Peng Liang, Gao Zhiliang, Xie Chan
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Key Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Oncotarget. 2016 Jan 5;7(1):929-45. doi: 10.18632/oncotarget.6137.
To identify the clinical and functional association of miR-214/199a/199a* cluster in human hepatocellular carcinoma (HCC) and to clarify the mechanism of miR-214.
Kaplan-Meier and Cox proportional regression analyses were used to determine the association of miR-214/199a/199a* cluster levels with the survival of HCC patients. The role of miR-214 in regulating HCC cell proliferation was studied with miR-214 mimics/inhibitor-treated cells. Furthermore, the inhibition effect of miR-214 on E2F2, cyclin-dependent kinase (CDK) 3 and CDK6 expression was assessed in HCC cell lines with miR-214 mimics/inhibitors to increase/decrease miR-214 expression. Direct binding of miR-214 to the 3'-untranslated regions of E2F2, CDK3, and CDK6 was verified by dual-luciferase reporter assay.
In analyzing HCC clinical specimens and cell lines, we discovered a uniform decrease in miR-214/199a/199a* expression in comparison with noncancerous tissue or normal liver epithelial cell lines. Higher miR-214 levels were related with improved patient survival. Overexpression of miR-214 in HCC cells inhibited proliferation by inducing G1-S checkpoint arrest. Conversely, RNA interference-mediated silencing of miR-214 promoted cell-cycle progression and accelerated the proliferation of HCC cells. E2F2, CDK3 and CDK6 were each directly targeted for inhibition by miR-214, and restoring their expression reversed miR-214 inhibition of cell-cycle progression. The relationship between expression of miR-214 and its targets was confirmed in HCC tumor xenografts and clinical specimens.
Our results demonstrate that miR-214 has tumor-suppressive activity in HCC through inhibition of E2F2, CDK3 and CDK6.
确定miR-214/199a/199a*簇在人类肝细胞癌(HCC)中的临床和功能关联,并阐明miR-214的作用机制。
采用Kaplan-Meier法和Cox比例回归分析来确定miR-214/199a/199a*簇水平与HCC患者生存的关联。用miR-214模拟物/抑制剂处理细胞,研究miR-214在调节HCC细胞增殖中的作用。此外,在HCC细胞系中用miR-214模拟物/抑制剂来增加/降低miR-214表达,评估miR-214对E2F2、细胞周期蛋白依赖性激酶(CDK)3和CDK6表达的抑制作用。通过双荧光素酶报告基因检测验证miR-214与E2F2、CDK3和CDK6的3'-非翻译区的直接结合。
在分析HCC临床标本和细胞系时,我们发现与癌旁组织或正常肝上皮细胞系相比,miR-214/199a/199a*表达一致降低。较高的miR-214水平与患者生存期改善相关。HCC细胞中miR-214的过表达通过诱导G1-S期检查点停滞来抑制增殖。相反,RNA干扰介导的miR-214沉默促进细胞周期进程并加速HCC细胞增殖。E2F2、CDK3和CDK6均为miR-214直接靶向抑制的对象,恢复它们的表达可逆转miR-214对细胞周期进程的抑制。miR-214与其靶标的表达关系在HCC肿瘤异种移植模型和临床标本中得到证实。
我们的结果表明,miR-214通过抑制E2F2、CDK3和CDK6在HCC中具有肿瘤抑制活性。